
Neuroendocrine Tumours (NETs) – Vitamin D (Cholecalciferol / Ergocalciferol)
Vitamin D deficiency is demonstrably more common in people with neuroendocrine tumours (NETs) — but that does not automatically mean your deficiency is caused by
It was 10th November 2010 just after midnight. I gradually woke up after a marathon 9-hour surgery – the first of what was to be several visits to an operating theatre. The last thing I remembered before going ‘under’ was the voices of the surgical staff. When I woke up, I remember it being dark and I appeared to be constrained and pinned down by the dozen or so tubes going in and out of my weak and battered body. I can still remember the feeling today; it was like I was pinned to the bed and I was completely vulnerable and helpless. However, what I remember most was my wife Chris holding my hand which gave me a great deal of much-needed comfort and security.
The build-up to this day began on 26 July 2010 when I was given the news that I had metastatic Neuroendocrine Tumours and that the prognosis without any treatment wasn’t too good making the decision to have treatment a lot easier. I told my Oncologist to ‘crack on’ with whatever treatment would be required.
However, it wasn’t that easy and as I was yet to find out, Neuroendocrine Cancer isn’t a simple disease. I first had to undergo a plethora of other tests including specialist scans, blood, and urine tests. The specialist scans (crucially) confirmed my tumours were ‘avid’ to something called a ‘somatostatin analogue‘. The scan also confirmed I had more tumours than initially thought. This was key to working out my treatment plan as I now had a grade, stage and I had the right tumour ‘receptors‘ to assist along the way.
When I initially presented in May 2010, I hadn’t realised for some months that I was showing symptoms of one of the Neuroendocrine Tumour syndromes (in my case carcinoid syndrome‘. This was mainly facial flushing but thinking back, there was some diarrhea albeit infrequent. The subsequent specialist blood and urine tests (CgA and 5HIAA respectively) were way out of range confirming both the diagnosis of tumour bulk and tumour activity, respectively. The tumour activity (or function) is one thing that makes NETs different from most cancers and is caused by excessive secretion of specific hormones applicable to the primary location of the tumour. Thus, why I had to be established on a ‘somatostatin analogue’ which is designed to inhibit excessive secretion. I self-injected Octreotide daily for 2 months until the flushing was under control. When certain Neuroendocrine Tumours cause carcinoid syndrome, there is a risk of a phenomenon known as ‘Carcinoid Crisis‘. This is the immediate onset of debilitating and life-threatening symptoms that can be triggered by several events including anaesthesia. As an additional precaution to prevent such complications, I was admitted on the 8th November 2010 to have an ‘Octreotide soak’ (Octreotide on a drip) prior to the surgery on 9th November 2010.
As is normal for such procedures, I had the risks explained to me. There seemed to be a lot of risks on the list and my surgeon, Mr Neil Pearce, carefully explained each one. Death was on the list, but I was happy to hear he had a 100% record on his ‘table’. Trust is an extremely important word when you’re in this situation.
As a snub to cancer, I refused the offer of a wheelchair and chose to walk to the operating theatre at around 2pm. So together with my ‘drip fed’ Octreotide trolley and wearing my surgical stockings and gown (carefully fastened at the rear!), I wandered down to the operating theatre with my escorting nurse. The anaesthetist injected the anaesthesia and commenced his countdown. It worked!
The 9-hour operation was designed to debulk what was described as “extensive intra-abdominal neuroendocrine disease”. The operation comprised the removal of 3 feet of the small intestine at the terminal ileum plus a right hemicolectomy, a mesenteric root dissection taking out the nodes on the superior mesenteric artery and a mesenteric vein reconstruction. With the assistance of a vascular surgeon, my NET surgeon also dissected out a dense fibrotic retro-peritoneal reaction that had encircled my aorta and cava below the level of the superior mesenteric artery. Phew! Thank goodness I was asleep! Read the remainder of my therapy story here.
When I woke up just after midnight on 10th Nov 2010, what I remember most was my wife Chris holding my hand which gave me a great deal of much-needed comfort and security.
One day per year doesn’t cut it for me, so on the basis you can never have enough awareness windows, for me, EVERY DAY IS WORLD NEUROENDOCRINE CANCER DAY and via my own social media channels, I’m making sure everyone knows!
Thanks for reading.
Blog Facebook. Like this page please.
Personal Facebook. Like this page please.
Awareness Facebook Like this page please.
Follow me on X (formerly twitter)
Check out my online presentations
Check out my WEGO Health Awards


Vitamin D deficiency is demonstrably more common in people with neuroendocrine tumours (NETs) — but that does not automatically mean your deficiency is caused by

Words are very important to cancer patients, some people hang their hats on them and put their feet up, and some people google them until

Overview Many thanks for the support in January and February 2026. This is a double month newsletter due to my 27 day holiday! 2026 Blog

Vitamin B12 deficiency is demonstrably more common in people with neuroendocrine tumours (NETs) – what that means is there is a chance your deficiency as

When I was a young lad, I didn’t seem to have a fear of heights, not that I got many chances to test it but

When I was diagnosed with metastatic Neuroendocrine Cancer in 2010, there’s a lot of milestones I doubted I would reach. One is today and I

A Phase 2/3, Multicenter, Randomized Open-Label Study of Zanzalintinib vs Everolimus in Participants With Previously Treated, Unresectable, Locally Advanced or Metastatic Neuroendocrine Tumors. The primary purpose

Long-axial field-of-view (LAFOV) systems have changed the field of molecular imaging. Since their introduction, many PET centres have installed these next-generation digital systems to provide

Crinetics Announces First Patient Dosed in Phase 1/2 Trial Evaluating CRN09682 for the Treatment of Neuroendocrine Tumours and Other Somatostatin Receptor 2-Expressing Tumours Read the

Buy me a cup of tea or two? Change the number below to increment. i.e insert 2 = £8, 3 = £12, etc
Overheads to run this site, e.g. software packages, domain registration fees, software tools, misc items. Donate £4 or more so I have the fuel to keep on providing great content!
£4.00
Subscribe to get the latest posts sent to your email.
Subscribe now to keep reading and get access to the full archive.